1 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Global Idiopathic Pulmonary Fibrosis Market: Market Characterization 6
2.1 Overview 6
2.2 Idiopathic Pulmonary Fibrosis Market Size 6
2.3 Idiopathic Pulmonary Fibrosis Market Forecast and CAGR 7
2.4 Drivers and Barriers for Idiopathic Pulmonary Fibrosis Market 9
2.4.1 Drivers for Idiopathic Pulmonary Fibrosis Market 9
2.4.2 Barriers for Idiopathic Pulmonary Fibrosis Market 9
2.5 Opportunity and Unmet Need 11
2.6 Key Takeaway 12
3 Idiopathic Pulmonary Fibrosis Market: Competitive Assessment 13
3.1 Overview 13
3.2 Strategic Competitor Assessment 13
3.3 Profiles of the Major Therapeutic Class in Idiopathic Pulmonary Fibrosis 14
3.3.1 Overview 14
3.3.2 Immunosuppresants 14
3.3.3 Anti-inflammatory Drugs 15
3.3.4 Antifibrotics 15
3.4 Key Takeaway 18
4 Idiopathic Pulmonary Fibrosis Market: Pipeline Assessment 19
4.1 Overview 19
4.2 Strategic Pipeline Assessment 19
4.2.1 Technology Trends Analytic Framework 19
4.3 Idiopathic Pulmonary Fibrosis Therapeutics – Promising Drugs under Clinical Development 20
4.4 Molecule Profile for Promising Drugs for Idiopathic Pulmonary Fibrosis under Clinical Development 22
4.4.1 Letairis (ambrisentan) 22
4.4.2 Tracleer (bosentan) 23
4.4.3 Enbrel (etanercept) 24
4.4.4 Veldona (Oral interferon alfa) 25
4.5 Idiopathic Pulmonary Fibrosis Therapeutics Market – Clinical Pipeline by Mechanism of Action 26
4.6 Idiopathic Pulmonary Fibrosis Pipeline – Pipeline by Clinical Phases of Development 27
4.6.1 Idiopathic Pulmonary Fibrosis Therapeutics – Phase III Clinical Pipeline 27
4.6.2 Idiopathic Pulmonary Fibrosis Therapeutics – Phase II Clinical Pipeline 28
4.6.3 Idiopathic Pulmonary Fibrosis Therapeutics – Phase I Clinical Pipeline 28
4.6.4 Idiopathic Pulmonary Fibrosis Therapeutics – Preclinical Pipeline 29
4.6.5 Idiopathic Pulmonary Fibrosis Therapeutics – Discovery Pipeline 29
4.7 Discontinued / Suspended Drug for Idiopathic Pulmonary Fibrosis 29
4.8 Key Takeaway 30
5 Idiopathic Pulmonary Fibrosis : Implications for Future Market Competition 31
6 Idiopathic Pulmonary Fibrosis Market: Future Players in the Idiopathic Pulmonary Fibrosis Market 33
6.1 Introduction 33
6.2 Gilead Sciences, Inc., California 33
6.2.1 Overview 33
6.2.2 Respiratory Disease Portfolio 35
6.2.3 Idiopathic Pulmonary Fibrosis Product Portfolio 35
6.3 Actelion Ltd. 36
6.3.1 Overview 36
6.3.2 Respiratory Disease Portfolio 37
6.3.3 Idiopathic Pulmonary Fibrosis Product Portfolio 37
6.4 Amgen Inc. 38
6.4.1 Overview 38
6.4.2 Respiratory Disease Portfolio 39
6.4.3 Idiopathic Pulmonary Fibrosis Product Portfolio 39
6.5 InterMune, Inc. 40
6.5.1 Overview 40
6.5.2 Respiratory Disease Portfolio 42
6.6 Amarillo Biosciences 43
6.6.1 Overview 43
6.6.2 Respiratory Disease Portfolio 44
6.6.3 Idiopathic Pulmonary Fibrosis Product Portfolio 44
7 Idiopathic Pulmonary Fibrosis Market: Appendix 46
7.1 Market Definitions 46
7.2 Abbreviations 46
7.3 Research Methodology 47
7.3.1 Coverage 48
7.3.2 Secondary Research 48
7.3.3 Forecasting 49
7.3.4 Primary Research 52
7.3.5 Expert Panel validation 52
7.4 Contact Us 52
7.5 Disclaimer 52
7.6 Sources 53
 

1.1 List of Tables
Table 1: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Revenues ($m), 2001–2009 7
Table 2: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Forecast ($m), 2009-2016 8
Table 3: Major Marketed Products Comparison in the Idiopathic Pulmonary Fibrosis Market, 2010 18
Table 4: Idiopathic Pulmonary Fibrosis Therapeutics – Most Promising Drugs Under Clinical Development, 2010 20
Table 5: Idiopathic Pulmonary Fibrosis Therapeutics – Phase III Clinical Pipeline, 2010 27
Table 6: Idiopathic Pulmonary Fibrosis Therapeutics – Phase II Clinical Pipeline, 2010 28
Table 7: Idiopathic Pulmonary Fibrosis Therapeutics – Phase I Clinical Pipeline, 2010 28
Table 8: Idiopathic Pulmonary Fibrosis Therapeutics – Preclinical Pipeline, 2010 29
Table 9: Idiopathic Pulmonary Fibrosis Therapeutics – Preclinical Pipeline, 2010 29
Table 10: List of Discontinued Drugs for Idiopathic Pulmonary Fibrosis, 2010 29
Table 11: Gilead Sciences, Inc. –Respiratory Pipeline Products, 2010 35
Table 12: Actelion Ltd. –Respiratory Pipeline Products, 2010 37
Table 13: Amgen Inc. – Respiratory Disease Pipeline Products, 2010 39
Table 14: InterMune, Inc– Respiratory Disease Pipeline Products, 2010 42
Table 15: Amarillo Biosciences - Respiratory Disease Pipeline Products, 2010 44
 

1.2 List of Figures
Figure 1: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Revenues ($m), 2001–2009 7
Figure 2: Idiopathic Pulmonary Fibrosis Therapeutics, Global, Market Forecast ($m), 2009-2016 8
Figure 3: Opportunity and Unmet Need in the Idiopathic Pulmonary Fibrosis Market, 2010 12
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Idiopathic Pulmonary Fibrosis, 2010 13
Figure 5: Technology Trends Analytic Framework of the Idiopathic Pulmonary Fibrosis Pipeline, 2010 19
Figure 6: Technology Trends Analytic Framework of the Idiopathic Pulmonary Fibrosis Pipeline – Description, 2010 20
Figure 7: Idiopathic Pulmonary Fibrosis Therapeutics – Clinical Pipeline by Mechanism of Action, 2010 26
Figure 8: Idiopathic Pulmonary Fibrosis Pipeline by Phase of Clinical Development, 2010 27
Figure 9: Implications for Future Market Competition in the Idiopathic Pulmonary Fibrosis Market, 2010 31
Figure 10: Idiopathic Pulmonary Fibrosis Therapeutics Market – Clinical Pipeline by Company, 2010 33
Figure 11: GlobalData Methodology, 2010 48
Figure 11: GlobalData Market Forecasting Model 51